IncyteMIL:1INCY +5.46%62 FCF Margin % is 27.83% as of Mar. 2026, which is 82% above its 10-year median of 15.32. GuruFocus rates MIL:1INCY with a GF Score™ of 62/100 and a GF Value™ of €88.40 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Incyte ranks better than 92.28% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Incyte's Free Cash Flow for the
three
months ended in Mar. 2026 was €306 Mil. Incyte's Revenue for the
three
months ended in Mar. 2026 was €1,101 Mil. Therefore, Incyte's FCF Margin % for the quarter that ended in Mar. 2026 was 27.83%.
The historical rank and industry rank for Incyte's FCF Margin % or its related term are showing as below:
MIL:1INCY'
s FCF Margin % Range Over the Past 10 Years
Min: -13.28 Med: 15.32 Max: 29.3
Current: 26.42
During the past 13 years, the highest FCF Margin % of Incyte was 29.30%. The lowest was -13.28%. And the median was 15.32%.
MIL:1INCY's FCF Margin % is ranked better than 92.28% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs MIL:1INCY: 26.42
Incyte FCF Margin % Related Terms
Incyte FCF Margin % Historical Data
* Premium members only.
The historical data trend for Incyte's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1INCY vs MRNA, ROIV, INSM: FCF Margin % Comparison
For the Biotechnology subindustry, Incyte's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Incyte's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (MIL:1INCY) has a FCF Margin % of 27.83% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Incyte and its competitors. This is 82% above median its historical median of 15.32. According to the industry distribution chart, Incyte ranks #74 out of 959 companies in the Biotechnology industry, placing it in the top 7.7%.
Is Incyte's FCF Margin % too high?
Incyte's current FCF Margin % of 27.83% is 82% above median its 10-year median of 15.32. Based on the distribution chart, Incyte ranks #74 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Incyte has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's FCF Margin % compare to MRNA and ROIV?
According to the Biotechnology industry distribution chart, Incyte ranks #74 out of 959 companies for FCF Margin %. This places Incyte in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Incyte and its competitors. Incyte's current FCF Margin % is 27.83%, which is 82% above median its own 10-year median of 15.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MIL:1INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is €88.40, compared to a current price of €101.20 — trading 14.5% above its estimated fair value. The current FCF Margin % is 27.83%, which is 82% above median its 10-year median of 15.32. Incyte's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Incyte (MIL:1INCY), the current FCF Margin % is 27.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MIL:1INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of €101.20 is trading 14.5% above its estimated GF Value™ of €88.40.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MIL:1INCY:
FCF Margin %: 27.83% (82% above median its 10-year median of 15.32)
GF Value™: €88.40 vs. price of €101.20 (14.5% above fair value)
No single metric tells the full story. See the MIL:1INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
62GF Score
Get the complete analysis for MIL:1INCY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1INCY has been successfully added to your 
